ethanolamine has been researched along with Pancreatic Neoplasms in 2 studies
Pancreatic Neoplasms: Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA).
| Excerpt | Relevance | Reference |
|---|---|---|
| "A number of bladder cancer case-control studies have noted an association with work as a machinist." | 2.40 | Oils and cancer. ( Tolbert, PE, 1997) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Battini, S | 1 |
| Faitot, F | 1 |
| Imperiale, A | 1 |
| Cicek, AE | 1 |
| Heimburger, C | 1 |
| Averous, G | 1 |
| Bachellier, P | 1 |
| Namer, IJ | 1 |
| Tolbert, PE | 1 |
1 review available for ethanolamine and Pancreatic Neoplasms
| Article | Year |
|---|---|
Oils and cancer.
Topics: 2-Naphthylamine; Benzo(a)pyrene; Carcinogens; Chlorine Compounds; Esophageal Neoplasms; Ethanolamine | 1997 |
1 other study available for ethanolamine and Pancreatic Neoplasms
| Article | Year |
|---|---|
Metabolomics approaches in pancreatic adenocarcinoma: tumor metabolism profiling predicts clinical outcome of patients.
Topics: Adenocarcinoma; Aged; Biomarkers; Chemotherapy, Adjuvant; Discriminant Analysis; Ethanolamine; Femal | 2017 |
Metabolomics approaches in pancreatic adenocarcinoma: tumor metabolism profiling predicts clinical outcome of patients.
Topics: Adenocarcinoma; Aged; Biomarkers; Chemotherapy, Adjuvant; Discriminant Analysis; Ethanolamine; Femal | 2017 |
Metabolomics approaches in pancreatic adenocarcinoma: tumor metabolism profiling predicts clinical outcome of patients.
Topics: Adenocarcinoma; Aged; Biomarkers; Chemotherapy, Adjuvant; Discriminant Analysis; Ethanolamine; Femal | 2017 |
Metabolomics approaches in pancreatic adenocarcinoma: tumor metabolism profiling predicts clinical outcome of patients.
Topics: Adenocarcinoma; Aged; Biomarkers; Chemotherapy, Adjuvant; Discriminant Analysis; Ethanolamine; Femal | 2017 |